Hepion Pharmaceuticals' Shares Fall After Merger Deal With Pharma Two B

MT Newswires Live07-23

Hepion Pharmaceuticals (HEPA) shares fell nearly 19% in recent Monday trading after the company said that it entered a merger deal with Pharma Two B, a private drug development company.

Per the agreement, Hepion will become a wholly-owned subsidiary of the Israeli company. The combined company will continue to operate under "Pharma Two B" name. The merger is set to close in Q4, the company said.

Pharma Two B plans to file a registration statement with the US Securities and Exchange Commission to issue shares to Hepion's shareholders and intends to list its shares on Nasdaq under the ticker symbol "PHTB".

The merger is valued at about $58.5 million in estimated equity and Pharma Two B expects to receive up to $11.5 million in gross cash proceeds when the deal closes. Net proceeds will be used for further development of parkinson's disease treatment candidate P2B001, and repay up to $2.9 million of Hepion's senior unsecured notes.

Price: 0.83, Change: -0.19, Percent Change: -18.63

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2453711635?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-23 02:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2453711635","market":"sh","top_or_hot":-1,"title":"Hepion Pharmaceuticals' Shares Fall After Merger Deal With Pharma Two B","media":"MT Newswires Live","content":"<html><body><p> Hepion Pharmaceuticals (HEPA) shares fell nearly 19% in recent Monday trading after the company said that it entered a merger deal with Pharma Two B, a private drug development company.</p><p>Per the agreement, Hepion will become a wholly-owned subsidiary of the Israeli company. The combined company will continue to operate under \"Pharma Two B\" name. The merger is set to close in Q4, the company said.</p><p>Pharma Two B plans to file a registration statement with the US Securities and Exchange Commission to issue shares to Hepion's shareholders and intends to list its shares on Nasdaq under the ticker symbol \"PHTB\".</p><p>The merger is valued at about $58.5 million in estimated equity and Pharma Two B expects to receive up to $11.5 million in gross cash proceeds when the deal closes. Net proceeds will be used for further development of parkinson's disease treatment candidate P2B001, and repay up to $2.9 million of Hepion's senior unsecured notes.</p><p>Price: 0.83, Change: -0.19, Percent Change: -18.63</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hepion Pharmaceuticals' Shares Fall After Merger Deal With Pharma Two B</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHepion Pharmaceuticals' Shares Fall After Merger Deal With Pharma Two B\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-23 02:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hepion Pharmaceuticals (HEPA) shares fell nearly 19% in recent Monday trading after the company said that it entered a merger deal with Pharma Two B, a private drug development company.Per the ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2453711635","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2453711635","pubTimestamp":1721673126,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Hepion Pharmaceuticals  shares fell nearly 19% in recent Monday trading after the company said that it entered a merger deal with Pharma Two B, a private drug development company.Per the agreement, Hepion will become a wholly-owned subsidiary of the Israeli company. The combined company will continue to operate under \"Pharma Two B\" name. The merger is set to close in Q4, the company said.Pharma Two B plans to file a registration statement with the US Securities and Exchange Commission to issue shares to Hepion's shareholders and intends to list its shares on Nasdaq under the ticker symbol \"PHTB\".The merger is valued at about $58.5 million in estimated equity and Pharma Two B expects to receive up to $11.5 million in gross cash proceeds when the deal closes. Net proceeds will be used for further development of parkinson's disease treatment candidate P2B001, and repay up to $2.9 million of Hepion's senior unsecured notes.Price: 0.83, Change: -0.19, Percent Change: -18.63","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","HEPA":"Hepion Pharmaceuticals, Inc."},"translate_title":"Hepion Pharmaceuticals与Pharma Two B合并后股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HEPA":0.9},"content_text":"Hepion Pharmaceuticals (HEPA) shares fell nearly 19% in recent Monday trading after the company said that it entered a merger deal with Pharma Two B, a private drug development company.Per the agreement, Hepion will become a wholly-owned subsidiary of the Israeli company. The combined company will continue to operate under \"Pharma Two B\" name. The merger is set to close in Q4, the company said.Pharma Two B plans to file a registration statement with the US Securities and Exchange Commission to issue shares to Hepion's shareholders and intends to list its shares on Nasdaq under the ticker symbol \"PHTB\".The merger is valued at about $58.5 million in estimated equity and Pharma Two B expects to receive up to $11.5 million in gross cash proceeds when the deal closes. Net proceeds will be used for further development of parkinson's disease treatment candidate P2B001, and repay up to $2.9 million of Hepion's senior unsecured notes.Price: 0.83, Change: -0.19, Percent Change: -18.63","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2453711635"}